Group 1 - The stock price of Shengda Bio reported at 18.64 yuan as of August 18, 2025, with a decrease of 0.14 yuan, representing a decline of 0.75% from the previous trading day [1] - The company specializes in the research, production, and sales of biotin, folic acid, and other vitamin products, which are widely used in feed, food, and pharmaceutical industries [1] - Shengda Bio's industry classification falls under the chemical products sector, involving synthetic biology and vitamins concepts [1] Group 2 - Shengda Bio announced the redemption of structured deposits amounting to 80 million yuan, which matured on August 15, resulting in a total recovery of 80.1193 million yuan, aligning with expected returns [1] - On August 18, the net outflow of main funds was 6.7311 million yuan, with a cumulative net outflow of 17.9616 million yuan over the past five days [1]

公司公告显示，已完成《公司章程》备案及工商变更登记手续，并取得浙江省市场监督管理局换发的 《营业执照》。 风险提示：股市有风险，投资需谨慎。 圣达生物股价报18.78元，较前一交易日上涨1.62%，成交额0.68亿元。 圣达生物主营业务为生物素、叶酸等维生素类产品的研发、生产和销售，产品广泛应用于饲料、食品、 医药等领域。公司所属板块包括化学制品、浙江板块、合成生物等。 ...

证券日报网讯 8月15日晚间，花园生物发布公告称，公司于2025年8月15日召开了第七届董事会第十一 次会议及第七届监事会第八次会议，审议通过了《关于部分募投项目重新论证并延期的议案》，同意公 司在募投项目实施主体、实施地点及投资规模不发生变更的情况下，延长"年产6000吨维生素A粉和 20000吨维生素E粉项目""年产5000吨维生素B6项目""年产200吨生物素项目"和"年产10000吨L-丙氨酸 （发酵法）及生物制造中试基地项目"达到预计可使用状态的日期。 （文章来源：证券日报） ...

消息面上，圣达生物预计2025年1-6月归属于上市公司股东的净利润为3500万元至4500万元，同比增长 112.19%至172.81%。 资金流向方面，8月5日主力资金净流出1687.95万元，近五日累计净流出3778.23万元。 风险提示：市场有风险，投资需谨慎。 截至2025年8月5日收盘，圣达生物股价报18.35元，较前一交易日下跌0.49%，成交额0.77亿元，换手率 2.44%。 圣达生物主营业务为生物素、叶酸等维生素类产品的研发、生产和销售，产品广泛应用于饲料、食品、 医药等领域。公司所属板块包括化学制品、合成生物、维生素等。 ...

Investment Rating - The investment rating for the company is maintained as "Buy" [2] Core Views - The prices of the main products, Vitamin B1 and B6, remain strong, contributing to profit growth. The company is a significant supplier in the global B vitamin market, holding leading market shares in Vitamin B6 and B1, with a revenue contribution of 78% from B vitamins in 2024. The prices for Vitamin B6 and B1 have shown year-on-year increases of 43.8% and 21.04% respectively in the first half of 2025, driving rapid profit growth [8][5] - The company is expanding its product line with new projects, including Vitamin B5 and Vitamin A, which are expected to enhance its long-term growth potential. The successful launch of these new products could significantly increase the company's market presence [8] - The financial forecast has been slightly adjusted, with expected net profits for 2025, 2026, and 2027 projected at 921 million, 1,063 million, and 1,070 million respectively. The corresponding PE ratios are estimated at 13, 11, and 11 times. The target market value for 2025 is set at 141 billion, indicating a 21% upside potential from the current market value [8][10] Financial Data and Profit Forecast - Total revenue is projected to grow from 2,209 million in 2024 to 2,708 million in 2025, with a year-on-year growth rate of 22.6%. The net profit is expected to increase from 651 million in 2024 to 921 million in 2025, reflecting a growth rate of 41.4% [7][12] - The gross margin is anticipated to improve from 42% in 2024 to 51.1% in 2025, while the return on equity (ROE) is expected to rise from 14.1% to 16.6% during the same period [7][12]

Group 1 - The company Zhejiang Shengda Bio-Pharm Co., Ltd. plans to issue shares to specific investors, with the total amount of funds raised not exceeding 267.61 million yuan [1][2] - The issuance has been approved by the Shanghai Stock Exchange and the China Securities Regulatory Commission [1][2] - The funds raised will be used for a project to produce 20,000 tons of D-isomeric ascorbic acid and its sodium salt, with a total investment of 368 million yuan [1][2] Group 2 - The issuance will involve no more than 51,356,687 shares, which is capped at 30% of the company's total share capital prior to the issuance [2][3] - The final number of shares to be issued will be determined based on the actual situation at the time of issuance [3] - Shares acquired through this issuance will be subject to a six-month lock-up period [3][4] Group 3 - The company has a plan for shareholder returns over the next three years (2023-2025), considering factors such as operational development and shareholder expectations [4] - The company will adjust the order and amount of funds allocated to projects if the actual funds raised are less than the planned investment [2][4] - The company has committed to measures to mitigate the impact of immediate return dilution on small investors [4][5] Group 4 - The company operates in the food and feed additive industry, focusing on products such as biotin and lactic acid bacteriocin [5][6] - The industry is experiencing rapid growth, but increased competition may affect profit margins [5][6] - The company has established a significant position in the market, being one of the earliest developers of biotin and biological preservatives in China [5][6]